JP2017527310A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527310A5 JP2017527310A5 JP2017533170A JP2017533170A JP2017527310A5 JP 2017527310 A5 JP2017527310 A5 JP 2017527310A5 JP 2017533170 A JP2017533170 A JP 2017533170A JP 2017533170 A JP2017533170 A JP 2017533170A JP 2017527310 A5 JP2017527310 A5 JP 2017527310A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric receptor
- domain
- pharmaceutical composition
- receptor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700010039 chimeric receptor Proteins 0.000 claims 22
- 210000002865 immune cell Anatomy 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 8
- 230000011664 signaling Effects 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 7
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 claims 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 5
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 5
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 5
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 5
- 230000000139 costimulatory effect Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000001086 cytosolic effect Effects 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 108020001756 ligand binding domains Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000003979 eosinophil Anatomy 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 210000002540 macrophage Anatomy 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- -1 CD3ζ Proteins 0.000 claims 2
- 108010087819 Fc receptors Proteins 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 1
- 101000831286 Homo sapiens Protein timeless homolog Proteins 0.000 claims 1
- 101000752245 Homo sapiens Rho guanine nucleotide exchange factor 5 Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 108010073816 IgE Receptors Proteins 0.000 claims 1
- 102000009438 IgE Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 230000003190 augmentative effect Effects 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960000455 brentuximab vedotin Drugs 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 229960001838 canakinumab Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000004940 costimulation Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047916P | 2014-09-09 | 2014-09-09 | |
| US62/047,916 | 2014-09-09 | ||
| PCT/US2015/049126 WO2016040441A1 (en) | 2014-09-09 | 2015-09-09 | Chimeric receptors and uses thereof in immune therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017527310A JP2017527310A (ja) | 2017-09-21 |
| JP2017527310A5 true JP2017527310A5 (enExample) | 2018-10-18 |
Family
ID=54151414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533170A Pending JP2017527310A (ja) | 2014-09-09 | 2015-09-09 | キメラ受容体および免疫療法におけるその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180133252A9 (enExample) |
| EP (1) | EP3191507A1 (enExample) |
| JP (1) | JP2017527310A (enExample) |
| KR (1) | KR20170073593A (enExample) |
| CN (1) | CN107074969A (enExample) |
| AU (1) | AU2015315199B2 (enExample) |
| BR (1) | BR112017004675A2 (enExample) |
| CA (1) | CA2972714A1 (enExample) |
| IL (1) | IL250828A0 (enExample) |
| MA (1) | MA40595A (enExample) |
| MX (1) | MX2017003062A (enExample) |
| SG (2) | SG10201902168PA (enExample) |
| WO (1) | WO2016040441A1 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512194B2 (en) | 2012-01-27 | 2016-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Modified IL-13 polypeptides |
| CN110615835A (zh) | 2012-08-09 | 2019-12-27 | 利兰斯坦福初级大学董事会 | 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法 |
| US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
| WO2015042705A1 (en) | 2013-09-24 | 2015-04-02 | Medicenna Biopharma Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| WO2015058018A1 (en) * | 2013-10-17 | 2015-04-23 | National University Of Singapore | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| JP2018515123A (ja) | 2015-05-18 | 2018-06-14 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| WO2017161333A1 (en) * | 2016-03-18 | 2017-09-21 | Unum Therapeutics | Modified chimeric receptors and uses thereof in immune therapy |
| WO2017205254A1 (en) * | 2016-05-23 | 2017-11-30 | Unum Therapeutics | Immune cells expressing antibody-coupled t-cell receptor (actr) for use in inhibiting cancer cells expressing surface immunoglobulin |
| EP3487877A4 (en) * | 2016-07-19 | 2020-01-01 | Unum Therapeutics Inc. | USE OF THE ANTIBODY COUPLED T CELL RECEPTOR (ACTR) WITH MULTIPLE CANCER ANTIBODIES IN THE TREATMENT OF CANCER |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| IL292551B2 (en) | 2016-10-07 | 2023-10-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| WO2018112266A1 (en) * | 2016-12-14 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| CN110494162A (zh) * | 2017-01-30 | 2019-11-22 | 优努姆治疗公司 | 改良的抗体-偶联t细胞受体构建体及其治疗用途 |
| JP2020507604A (ja) * | 2017-02-17 | 2020-03-12 | ユーナム・セラピューティクス・インコーポレイテッドＵｎｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | がん療法およびｂ細胞障害における抗ｂｃｍａ抗体および抗体結合ｔ細胞受容体（ａｃｔｒ）の併用 |
| CA3056115A1 (en) | 2017-03-16 | 2018-09-20 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 |
| BR112019020168A2 (pt) | 2017-03-27 | 2020-06-02 | F. Hoffmann-La Roche Ag | Receptores de ligação ao antígeno, células t transduzidas, polinucleotídeo isolado, vetor, kits, métodos para tratar uma doença e para induzir a lise de uma célula alvo e uso do receptor de ligação ao antígeno |
| MX2019011656A (es) * | 2017-03-27 | 2019-12-02 | Hoffmann La Roche | Formatos mejorados de receptor de union a antigeno. |
| BR112019020001A2 (pt) | 2017-03-27 | 2020-04-28 | Nat Univ Singapore | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| KR102687149B1 (ko) | 2017-06-07 | 2024-07-24 | 씨젠 인크. | 감소된 표면 푸코실화를 갖는 t 세포 및 이를 생산하고 사용하는 방법 |
| CA3072908A1 (en) * | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | Strep-tag specific binding proteins and uses thereof |
| US12274735B2 (en) | 2017-10-10 | 2025-04-15 | Medicenna Therapeutics Inc. | IL-4-fusion formulations for treatment of central nervous system (CNS) tumors |
| AU2018355462B9 (en) * | 2017-10-26 | 2022-04-28 | Regents Of The University Of Minnesota | Recombinant immune cells, methods of making, and methods of use |
| CN111295189B (zh) * | 2017-11-01 | 2023-09-15 | 艾洛基治疗公司 | 修饰的胱天蛋白酶-9多肽及其使用方法 |
| BR112020008568A2 (pt) * | 2017-11-09 | 2020-10-06 | Sangamo Therapeutics, Inc. | modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish) |
| AU2018365080B2 (en) | 2017-11-10 | 2025-07-24 | Jura Bio, Inc. | Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases |
| EP3707160A1 (en) | 2017-11-10 | 2020-09-16 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting tumor antigens |
| EA202091509A1 (ru) | 2017-12-19 | 2020-09-22 | Акуос, Инк. | Aav-опосредованная доставка терапевтических антител во внутреннее ухо |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| WO2019134001A1 (en) * | 2017-12-29 | 2019-07-04 | City Of Hope | Meditope-enabled t cells |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| KR102593359B1 (ko) * | 2018-03-19 | 2023-10-24 | 사바 라이프 사이언스 에이비 | Adcc 및 adcp 활성의 향상된 정량화를 위한 시스템 및 제품 |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| IL321548A (en) * | 2018-05-22 | 2025-08-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
| CN112638402A (zh) | 2018-07-03 | 2021-04-09 | Sotio有限责任公司 | 与增强葡萄糖输入的反式代谢分子组合的嵌合受体及其治疗用途 |
| US12077785B2 (en) | 2018-08-14 | 2024-09-03 | Sotio Biotech Inc. | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof |
| AU2019330347B2 (en) | 2018-08-29 | 2025-07-24 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| US20240165232A1 (en) * | 2018-09-24 | 2024-05-23 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CA3133037A1 (en) * | 2019-03-19 | 2020-09-24 | Ramot At Tel-Aviv University Ltd. | T cell expressing an fc gamma receptor and methods of use thereof |
| BR112021019571A2 (pt) | 2019-04-19 | 2021-12-07 | Chugai Pharmaceutical Co Ltd | Receptor quimérico que reconhece o sítio de modificação do anticorpo |
| US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| CN110592014A (zh) * | 2019-08-14 | 2019-12-20 | 广东美赛尔细胞生物科技有限公司 | 一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法 |
| MX2022002613A (es) | 2019-09-03 | 2022-06-02 | Myeloid Therapeutics Inc | Metodos y composiciones para la integracion del genoma. |
| CN111944062B (zh) * | 2019-12-09 | 2023-11-07 | 深圳市体内生物医药科技有限公司 | 一种识别Fc片段的嵌合抗原受体及其应用 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN111100942B (zh) * | 2019-12-31 | 2023-03-28 | 海南波莲水稻基因科技有限公司 | 与水稻光温敏核雄性不育表型相关的分子标记和应用 |
| JP7466231B2 (ja) * | 2020-02-13 | 2024-04-12 | 四川大学 | キメラ抗原受容体及びその適用 |
| EP3875478A1 (en) * | 2020-03-05 | 2021-09-08 | Canvax Biotech, S.L. | Novel non-immunogenic chimeric antigen receptors and uses thereof |
| AU2021294559A1 (en) | 2020-06-22 | 2023-02-23 | Ramot At Tel-Aviv University Ltd. | Multi subunit protein modules, cells expressing same and uses thereof |
| CN113583139A (zh) * | 2020-07-06 | 2021-11-02 | 上海鑫湾生物科技有限公司 | 一种嵌合受体及其应用 |
| TW202220677A (zh) | 2020-07-31 | 2022-06-01 | 日商中外製藥股份有限公司 | 含有表現嵌合受體之細胞的醫藥組成物 |
| CN111876382A (zh) * | 2020-08-14 | 2020-11-03 | 上海星华生物医药科技有限公司 | 一种制备通用型免疫细胞的方法及其应用 |
| JP7618295B2 (ja) * | 2020-08-14 | 2025-01-21 | シャンハイ・シンフア・バイオ・ファーマスーティカル・サイエンス・アンド・テクノロジー・カンパニー・リミテッド | ユニバーサル免疫細胞の製造方法及びその応用 |
| JP2023549140A (ja) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス，インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびその使用方法 |
| CR20230228A (es) | 2020-12-01 | 2023-07-18 | Akouos Inc | Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular |
| AU2021409653A1 (en) * | 2020-12-22 | 2023-07-06 | Immunitybio, Inc. | Fc-receptor car constructs and cells |
| WO2022150379A1 (en) * | 2021-01-08 | 2022-07-14 | Regents Of The University Of Minnesota | Nk cell engager molecules and methods of use |
| AU2022237618A1 (en) | 2021-03-17 | 2023-10-12 | Create Medicines, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| JP2024536859A (ja) | 2021-09-27 | 2024-10-08 | ソティオ バイオテック インコーポレイティド | 解糖経路からグルコース代謝産物を再誘導するトランス代謝分子と組み合わせたキメラ受容体ポリペプチド及びその治療的使用 |
| EP4433515A1 (en) | 2021-11-16 | 2024-09-25 | SOTIO Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| CN114685662B (zh) * | 2022-03-30 | 2022-12-27 | 河北森朗生物科技有限公司 | 抗cd7纳米抗体、衍生物及其在肿瘤治疗中的应用 |
| EP4572787A1 (en) | 2022-08-19 | 2025-06-25 | SOTIO Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
| WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
| WO2024102954A1 (en) * | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024215989A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| WO2024233299A2 (en) * | 2023-05-05 | 2024-11-14 | Board Of Regents, The University Of Texas System | Multi-receptor natural killer cells |
| WO2025103439A1 (zh) * | 2023-11-16 | 2025-05-22 | 广州瑞风生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| KR102764613B1 (ko) * | 2024-03-28 | 2025-02-12 | 한양대학교 에리카산학협력단 | NaPi2b 특이적 CAR-T를 포함하는 난소암 치료용 약학 조성물 |
| WO2025235862A1 (en) * | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| JPH09501055A (ja) | 1993-07-30 | 1997-02-04 | ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー | 初代リンパ球への効率的遺伝子転移 |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| US5756910A (en) | 1996-08-28 | 1998-05-26 | Burgett, Inc. | Method and apparatus for actuating solenoids in a player piano |
| WO1998022588A2 (en) | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| KR20010081111A (ko) | 1998-12-01 | 2001-08-27 | 제넨테크, 인크. | 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산 |
| US7052906B1 (en) | 1999-04-16 | 2006-05-30 | Celltech R & D Limited | Synthetic transmembrane components |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US8822647B2 (en) * | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| NZ606427A (en) | 2009-02-03 | 2014-10-31 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
| DE102009013748B4 (de) * | 2009-03-17 | 2012-01-26 | Paul-Ehrlich-Institut | Bestimmung von Interaktionen konstanter Antikörperteile mit Fc-gamma Rezeptoren |
| WO2011041093A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG11201400527XA (en) | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
| WO2015058018A1 (en) * | 2013-10-17 | 2015-04-23 | National University Of Singapore | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors |
| US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| WO2015179833A1 (en) * | 2014-05-23 | 2015-11-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating antibody resistance |
-
2015
- 2015-09-09 US US15/509,133 patent/US20180133252A9/en not_active Abandoned
- 2015-09-09 KR KR1020177009209A patent/KR20170073593A/ko not_active Withdrawn
- 2015-09-09 WO PCT/US2015/049126 patent/WO2016040441A1/en not_active Ceased
- 2015-09-09 CA CA2972714A patent/CA2972714A1/en not_active Abandoned
- 2015-09-09 MX MX2017003062A patent/MX2017003062A/es unknown
- 2015-09-09 CN CN201580048652.5A patent/CN107074969A/zh active Pending
- 2015-09-09 MA MA040595A patent/MA40595A/fr unknown
- 2015-09-09 SG SG10201902168PA patent/SG10201902168PA/en unknown
- 2015-09-09 AU AU2015315199A patent/AU2015315199B2/en not_active Ceased
- 2015-09-09 BR BR112017004675A patent/BR112017004675A2/pt not_active IP Right Cessation
- 2015-09-09 JP JP2017533170A patent/JP2017527310A/ja active Pending
- 2015-09-09 EP EP15767396.3A patent/EP3191507A1/en not_active Withdrawn
- 2015-09-09 SG SG11201701775VA patent/SG11201701775VA/en unknown
-
2017
- 2017-02-27 IL IL250828A patent/IL250828A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527310A5 (enExample) | ||
| JP7689161B2 (ja) | 多機能性免疫細胞療法 | |
| EP3472205B1 (en) | Chimeric antigen receptor | |
| CN109496217B (zh) | 具有cd3结合域的基于多聚体il-15的分子的构造和表征 | |
| JP2024105296A (ja) | Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質 | |
| CN110300603B (zh) | Cd47-car-t细胞 | |
| CN112074279A (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| CN109310762A (zh) | 联合疗法 | |
| JP7749319B2 (ja) | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 | |
| CN108250303B (zh) | 单域抗体融合蛋白及其应用 | |
| RS59373B1 (sr) | Vezujući molekuli za bcma i cd3 | |
| RS64870B1 (sr) | Imunomodulatorni proteini varijante pd-l1 i njihove upotrebe | |
| CA2924252A1 (en) | Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions | |
| RS66502B1 (sr) | Bispecifični ili-kapijski himerni antigenski receptor koji reaguje na cd19 i cd20 | |
| TW201536805A (zh) | 具有結合ＣＤ３２Ｂ和ＣＤ７９ｂ能力的雙特異性單價Ｆｃ雙抗體及其用途 | |
| CN109789164B (zh) | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 | |
| KR20220025698A (ko) | 다기능 융합 단백질 및 이의 용도 | |
| WO2022148410A1 (zh) | 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| CN117425484A (zh) | 多功能免疫细胞疗法 | |
| CN113474012B (zh) | Epcam抗体和epcam-car-t细胞 | |
| CN111465618A (zh) | 双特异性cd16-结合分子及其在疾病治疗中的用途 | |
| WO2020112529A1 (en) | Car-t cells having humanized cd19 scfv with mutation in cdr 1 region | |
| JP2024517773A (ja) | キメラＦｃα受容体及びその使用 | |
| CN113271965B (zh) | Cd37抗体和cd37-car-t细胞 | |
| CN121443631A (zh) | 用于治疗格雷夫斯病的ig样融合蛋白 |